A cross-linked anti-TNF-α aptamer for neutralization of TNF-α-induced cutaneous Shwartzman phenomenon: A simple and novel approach for improving aptamers' affinity and efficiency.
Shwartzman phenomenon
TNF-α
aptamer
multivalent aptamer
trimethyl aconitate
Journal
Biotechnology progress
ISSN: 1520-6033
Titre abrégé: Biotechnol Prog
Pays: United States
ID NLM: 8506292
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
26
06
2021
received:
27
05
2021
accepted:
01
07
2021
pubmed:
5
7
2021
medline:
1
3
2022
entrez:
4
7
2021
Statut:
ppublish
Résumé
To increase the efficiency of aptamers to their targets, a simple and novel method has been developed based on aptamer oligomerization. To this purpose, previously anti-human TNF-α aptamer named T1-T4 was trimerized through a trimethyl aconitate core for neutralization of in vitro and in vivo of TNF-α. At first, 54 mer T1-T4 aptamers with 5'-NH
Substances chimiques
Aptamers, Nucleotide
0
Tumor Necrosis Factor Inhibitors
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3191Informations de copyright
© 2021 American Institute of Chemical Engineers.
Références
Gül A. Dynamics of inflammatory response in autoinflammatory disorders: autonomous and hyperinflammatory states. Front Immunol. 2018;9:2422.
Asadzadeh-Aghdaei H, Mashayekhi K, Koushki K, et al. V617F-independent upregulation of JAK2 gene expression in patients with inflammatory bowel disease. J Cell Biochem. 2019;120(9):15746-15755. https://doi.org/10.1002/jcb.28844
Chahin AB, Opal JM, Opal SM. Whatever happened to the Shwartzman phenomenon? Innate Immun. 2018;24(8):466-479. https://doi.org/10.1177/1753425918808008
Movat HZ, Burrowes C, Cybulsky M, Dinarello C. Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and microvascular injury. Am J Pathol. 1987;129(3):463.
Kinoshita M, Nakashima M, Nakashima H, Seki S. Immune mechanisms underlying susceptibility to endotoxin shock in aged hosts: implication in age-augmented generalized Shwartzman reaction. Int J Mol Sci. 2019;20(13):3260. https://doi.org/10.3390/ijms20133260
Piguet P, Grau G, Vassalli P. Subcutaneous perfusion of tumor necrosis factor induces local proliferation of fibroblasts, capillaries, and epidermal cells, or massive tissue necrosis. Am J Pathol. 1990;136(1):103.
Grau G, Vesin C, De Groote D, et al. Prevention of human TNF-induced cutaneous Shwartzmann reaction and acute mortality in mice treated with anti-human TNF monoclonal antibodies. Clin Exp Immunol. 1991;84(3):411.
van Mulligen E, de Jong PHP, Kuijper TM, et al. Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study. Ann Rheum Dis. 2019;78(6):746-753. https://doi.org/10.1136/annrheumdis-2018-214970
Peyrin-Biroulet L. Anti-TNF therapy in inflammatory bowel diseases: a huge review. Minerva Gastroenterol Dietol. 2010;56(2):233-243.
Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165-178. https://doi.org/10.1136/annrheumdis-2012-202545
Connor V. Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int. 2011;31(3):327-337. https://doi.org/10.1007/s00296-009-1292-x
Van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol. 2013;9(3):164. https://doi.org/10.1038/nrrheum.2013.4
Blind M, Blank M. Aptamer selection technology and recent advances. Mol Ther Nucleic Acids. 2015;4:e223. https://doi.org/10.1038/mtna.2014.74
Mashayekhi K, Ganji A, Sankian M. Designing a new dimerized anti human TNF-α aptamer with blocking activity. Biotechnol Dent Prog. 2020;36(4):e2969. https://doi.org/10.1002/btpr.2969
Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science. 1990;249(4968):505-510. https://doi.org/10.1126/science.2200121
Ilgu M, Nilsen-Hamilton M. Aptamers in analytics. Analyst. 2016;141(5):1551-1568. https://doi.org/10.1039/C5AN01824B
Santulli-Marotto S, Nair SK, Rusconi C, Sullenger B, Gilboa E. Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity. Cancer Res. 2003;63(21):7483-7489.
Kim Y, Cao Z, Tan W. Molecular assembly for high-performance bivalent nucleic acid inhibitor. Proc Natl Acad Sci U S A. 2008;105(15):5664-5669.
Li Z, Hu Y, An Y, Duan J, Li X, Yang X-D. Novel bispecific aptamer enhances immune cytotoxicity against MUC1-positive tumor cells by MUC1-CD16 dual targeting. Molecules. 2019;24(3):478. https://doi.org/10.3390/molecules24030478
Lai W-Y, Wang J-W, Huang B-T, Lin EP-Y, Yang P-C. A novel TNF-α-targeting aptamer for TNF-α-mediated acute lung injury and acute liver failure. Theranostics. 2019;9(6):1741.
Hasegawa H, Taira KI, Sode K, Ikebukuro K. Improvement of aptamer affinity by dimerization. Sensors. 2008;8(2):1090-1098. https://doi.org/10.3390/s8021090
Singh AK, Das S, Datta A. A case study on the myth of emission from aliphatic amides. Methods Appl Fluoresc. 2016;4(4):047003. https://doi.org/10.1088/2050-6120/4/4/047003
Orava EW, Jarvik N, Shek YL, Sidhu SS, Gariépy J. A short DNA aptamer that recognizes TNFα and blocks its activity in vitro. ACS Chem Biol. 2012;8(1):170-178.
Moghadam M, Sankian M, Abnous K, et al. Cell-SELEX-based selection and characterization of a G-quadruplex DNA aptamer against mouse dendritic cells. Int Immunopharmacol. 2016;36:324-332. https://doi.org/10.1016/j.intimp.2016.04.042
Ythier A, Gascon M-P, Juillard P, Vesin C, Wallach D, Grau GE. Protective effect of natural TNF-binding protein on human TNF-induced toxicity in mice. Cytokine. 1993;5(5):459-462. https://doi.org/10.1016/1043-4666(93)90036-5
Rothstein JL, Schreiber H. Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice. Proc Natl Acad Sci U S A. 1988;85(2):607-611.
Penington AJ, Craft RO, Mitchell G, Morrison WA. Local Shwartzman reaction in the rat induced by endotoxin and ischemia: potential model for skin necrosis in meningococcemia. Pediatr Res. 2006;60(2):158-160. https://doi.org/10.1203/01.pdr.0000228326.99650.19
Müller J, Wulffen B, Pötzsch B, Mayer G. Multidomain targeting generates a high-affinity thrombin-inhibiting bivalent aptamer. Chembiochem. 2007;8(18):2223-2226. https://doi.org/10.1002/cbic.200700535
Vorobyeva M, Vorobjev P, Venyaminova A. Multivalent aptamers: versatile tools for diagnostic and therapeutic applications. Molecules. 2016;21(12):1613. https://doi.org/10.3390/molecules21121613
Zhang P, Sun F, Liu S, Jiang S. Anti-PEG antibodies in the clinic: current issues and beyond PEGylation. J Control Release. 2016;244:184-193. https://doi.org/10.1016/j.jconrel.2016.06.040
Grell M, Wajant H, Zimmermann G, Scheurich P. The type 1 receptor (CD120a) is the high-affinity receptor for soluble tumor necrosis factor. Proc Natl Acad Sci U S A. 1998;95(2):570-575.
Riese SB, Buscher K, Enders S, Kuehne C, Tauber R, Dernedde J. Structural requirements of mono-and multivalent L-selectin blocking aptamers for enhanced receptor inhibition in vitro and in vivo. Nanomed Nanotechnol Biol Med. 2016;12(4):901-908. https://doi.org/10.1016/j.nano.2015.12.379
Ghahremani F, Shahbazi-Gahrouei D, Kefayat A, Motaghi H, Mehrgardi MA, Javanmard SH. AS1411 aptamer conjugated gold nanoclusters as a targeted radiosensitizer for megavoltage radiation therapy of 4T1 breast cancer cells. RSC Adv. 2018;8(8):4249-4258. https://doi.org/10.1039/C7RA11116A
Guo X, Zhu X, Gao J, Liu D, Dong C, Jin X. PLGA nanoparticles with CD133 aptamers for targeted delivery and sustained release of propranolol to hemangioma. Nanomed J. 2017;12(21):2611-2624. https://doi.org/10.2217/nnm-2017-0130
Haruta K, Otaki N, Nagamine M, et al. A novel PEGylation method for improving the pharmacokinetic properties of anti-interleukin-17A RNA aptamers. Nucleic Acid Ther. 2017;27(1):36-44. https://doi.org/10.1089/nat.2016.0627
Ahn SY, Maeng Y-S, Kim YR, Choe YH, Hwang HS, Hyun Y-M. In vivo monitoring of dynamic interaction between neutrophil and human umbilical cord blood-derived mesenchymal stem cell in mouse liver during sepsis. Stem Cell Res Ther. 2020;11(1):44.
Mease P. Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors. Ann Rheum Dis. 2002;61(4):298-304.
Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFα in pulmonary pathophysiology. Respir Res. 2006;7(1):125.
Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol. 2015;60(6):575-589. https://doi.org/10.1016/j.survophthal.2015.06.004
Lakhin A, Tarantul V, Gening L. Aptamers: problems, solutions and prospects. Acta Naturae. 2013;5(4):19.